What did Accelmed Partners pay for Bioness (Bioventus)?

Accelmed Partners acquired Bioness (Bioventus) for $45.0M in 2024 (7.5x EBITDA), equivalent to 0.90x revenue. Target revenue was approximately $50.0M. Target EBITDA was approximately $6.0M.

What does Bioness (Bioventus) do?

Bioness (Bioventus) is a medical devices business.

What multiple did Accelmed Partners pay for Bioness (Bioventus)?

7.5x EBITDA and 0.90x revenue, based on disclosed deal value of $45.0M and disclosed financials.

M&A TRANSACTION · 2024

Bioness (Bioventus) acquired by Accelmed Partners

$45.0M· 7.5x EBITDA· 0.90x revenue

Target

Bioness (Bioventus)

Acquirer

Accelmed Partners

Disclosed financials at time of acquisition

Revenue

$50.0M

EBITDA

$6.0M

Deal Value

$45.0M

EV/EBITDA

7.5x

Context

This $45.0M acquisition of Bioness (Bioventus) by Accelmed Partners sits in the medical devices sub-vertical. The 7.5x EBITDA multiple paid in 2024 can be compared against the population median for medical devices transactions of similar size on our Medical Devices valuation hub.

Source

Data sourced from Press releases. All figures reflect disclosed values at the time of the acquisition; no estimated or imputed data. Methodology

Value your own medical devices

Get an instant valuation range for your business. Backed by 25,592 real M&A transactions.

Compare your business to the Bioness (Bioventus) acquisition.

Citation: ExitValue.ai. (2024). Bioness (Bioventus) acquired by Accelmed Partners. https://exitvalue.ai/deals/bioness-bioventus-acquired-by-accelmed-partners-hc-2024-0022